for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Accelerate Diagnostics Inc

AXDX.OQ

Latest Trade

16.21USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

10.25

 - 

24.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
16.21
Open
--
Volume
--
3M AVG Volume
4.48
Today's High
--
Today's Low
--
52 Week High
24.00
52 Week Low
10.25
Shares Out (MIL)
54.64
Market Cap (MIL)
878.14
Forward P/E
-10.33
Dividend (Yield %)
--

Latest Developments

More

Accelerate Diagnostics Reports Q3 Loss Per Share Of $0.37

Accelerate Diagnostics says On Aug 20, Co And Entity Affiliated With Phillips Entered Into Securities Purchase Agreement

Accelerate Diagnostics Reports Q2 Loss Per Share $0.38

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Accelerate Diagnostics Inc

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company's in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

Industry

Scientific & Technical Instr.

Contact Info

3950 S. Country Club Road #470

Building 3-307

+1.303.8638088

http://acceleratediagnostics.com/

Executive Leadership

John Patience

Independent Chairman of the Board

Lawrence Mehren

President, Chief Executive Officer, Director

Steve Reichling

Chief Financial Officer

John Phillips

Chief Operating Officer

Ron Price

Senior Vice President and Head of Commercial Operations, Americas

Key Stats

2.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.290

2017

-1.160

2018

-1.620

2019(E)

-1.556
Price To Earnings (TTM)
--
Price To Sales (TTM)
114.81
Price To Book (MRQ)
85.92
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1,247.01
LT Debt To Equity (MRQ)
1,247.01
Return on Investment (TTM)
-50.64
Return on Equity (TTM)
-48.95

Latest News

Latest News

BRIEF-Accelerate Diagnostics Q1 Loss Per Share $0.37

* Q1 EARNINGS PER SHARE VIEW $-0.32 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Accelerate Diagnostics announces pricing of $150 mln notes offering

* ACCELERATE DIAGNOSTICS, INC. ANNOUNCES PRICING OF $150 MILLION CONVERTIBLE NOTES OFFERING

BRIEF-Accelerate Diagnostics Announces $150 Mln Convertible Notes Offering

* ACCELERATE DIAGNOSTICS INC. ANNOUNCES $150 MILLION CONVERTIBLE NOTES OFFERING

BRIEF-Accelerate Diagnostics Qtrly Net Loss $0.27 Per Share

* ACCELERATE DIAGNOSTICS REPORTS Q4 AND FULL-YEAR FINANCIAL RESULTS FOR 2017

BRIEF-Accelerate Diagnostics says ‍on Nov 14, board increased its size to 8 members​

* Accelerate Diagnostics says on Nov 14, board increased size of board to 8 members - SEC Filing Source text: [http://bit.ly/2iocMIO] Further company coverage:

BRIEF-Accelerate Diagnostics reports Q3 loss per share $0.31

* Accelerate Diagnostics Inc reports q3 2017 financial results

BRIEF-Plaintiffs dismiss class action appeal against Accelerate Diagnostics

* Plaintiffs dismiss class action appeal against Accelerate Diagnostics

BRIEF-Accelerate Diagnostics reports Q2 loss per share $0.31

* Accelerate Diagnostics reports Q2 2017 financial results, doubles revenue generating placements

BRIEF-Accelerate Diagnostics announces closing of $79.3 mln upsized offering

* Accelerate Diagnostics announces closing of $79.3 million upsized offering Source text for Eikon: Further company coverage:

BRIEF-Accelerate Diagnostics prices upsized offering of 2.75 mln shares at $28.85 per share

* Accelerate diagnostics announces pricing of upsized public offering of common stock

BRIEF-Accelerate Diagnostics reports Q1 sales $530,000

* Accelerate Diagnostics reports 191 instruments under contract and 3x revenue growth for first quarter 2017

BRIEF-Accelerate Diagnostics reports Q1 sales $530,000

* Accelerate Diagnostics reports 191 instruments under contract and 3X revenue growth for first quarter 2017

BRIEF-Accelerate Diagnostics names Tom Brown to board of directors

* Accelerate Diagnostics names Tom Brown to board of directors

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up